ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) and RYTHM (NASDAQ:RYM – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
Volatility & Risk
ARS Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, RYTHM has a beta of 9.46, suggesting that its stock price is 846% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for ARS Pharmaceuticals and RYTHM, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
ARS Pharmaceuticals presently has a consensus price target of $25.00, suggesting a potential upside of 482.75%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than RYTHM.
Earnings & Valuation
This table compares ARS Pharmaceuticals and RYTHM”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $84.28 million | 5.06 | -$171.30 million | ($2.18) | -1.97 |
| RYTHM | $17.28 million | 2.09 | -$33.26 million | ($10.53) | -1.57 |
RYTHM has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ARS Pharmaceuticals and RYTHM’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
| RYTHM | -6.20% | -12.57% | -2.60% |
Insider and Institutional Ownership
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.0% of RYTHM shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of RYTHM shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
ARS Pharmaceuticals beats RYTHM on 8 of the 13 factors compared between the two stocks.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
About RYTHM
Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
